



UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

G. SCHMIDMAIER et al.

RECEIVED

JUL 10 2001

Application No.: 09/801,752

Group Art Unit: 1646 TECH CENTER 1600/2900

Filed: March 9, 2001

Examiner: Unassigned

For: BIOLOGICALLY ACTIVE IMPLANTS

Attorney Docket No.: 8932-148

**THIRD INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97 AND § 1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to Applicants' duty of disclosure under 37 C.F.R. § 1.97 and 1.98, enclosed is a Form PTO-1449 which lists 52 references in reverse chronological order, copies of which are enclosed for the Examiner's convenience.

It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the Form PTO-1449.

No fee is believed to be due for this submission, since it is being made before an initial Office Action on the merits of the above-identified application. Should any fee be required, however, please charge such fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date July 3, 2001

For

Paul D. Bianco
Brian M. Poissant

Reg. No. 43,500
Reg. No. 28,462

PENNIE & EDMONDS LLP
1667 K Street, N.W.
Washington, DC 20006
(202) 496-4400

Enclosures



RECEIVED

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8932-148	1111 10 2001 09/801,752
	APPLICANT	G. SCHMIDMAIER et al. TECH CENTER 1600/2900
	FILING DATE	GROUP
March 9, 2001		1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,086,908	7/2000	Göpferich	424	424	
	AB	5,916,585	6/1999	Cook et al.	424	426	
	AC	5,707,877	1/1998	Siiman et al.	436	518	
	AD	5,686,116	11/1997	Bockman et al.	424	650	
	AE	5,656,598	8/1997	Dunstan et al.	514	12	
	AF	5,645,592	7/1997	Nicolais et al.	623	16	
	AG	5,635,571	6/1997	Frechet et al.	525	410	
	AH	5,614,496	3/1997	Dunstan et al.	514	12	
	AI	5,603,715	2/1997	Kessler	606	63	
	AJ	5,556,645	9/1996	Bockman et al.	424	650	
	AK	5,502,074	3/1996	Cullinan et al.	514	443	
	AL	5,466,609	11/1995	Siiman et al.	436	518	
	AM	4,983,581	1/1991	Antoniades et al.	514	12	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	*Abstract Only
							YES	
	AN	WO 98/19699	5/1998	PCT				
	AO	WO 98/16268	4/1998	PCT				
	AP	WO 98/03695	1/1998	PCT				
	AQ	EP 0 816 413 A2	1/1998	Europe				
	AR	WO 97/38741	10/1997	PCT				*X
	AS	WO 97/34953	9/1997	PCT				
	AT	WO 97/32594	9/1997	PCT				
	AU	WO 97/24369	7/1997	PCT				
	AV	WO 96/38167	12/1996	PCT				
	AW	WO 96/28196	9/1996	PCT				
	AX	EP 0 719 562 A1	7/1996	Europe				*X
	AY	WO 96/18591	6/1996	PCT				
	AZ	WO 96/05825	2/1996	PCT				
	BA	WO 96/00592	1/1996	PCT				
	BB	DE 195 11 243 A1	1/1996	Germany				*X
	BC	WO 95/24211	9/1995	PCT				
	BD	0 636 377 A1	2/1995	Europe				

BE	WO 94/08635	4/1994	PCT			
BF	WO 94/03159	2/1994	PCT			
BG	DE 41 30 546 A1	3/1993	Germany		*X	
BH	DE 41 30 545 A1	3/1993	Germany		*X	
BI	WO 91/11148	8/1991	PCT			
BJ	DE 39 33 217 A1	4/1991	Germany		*X	
BK	WO 90/13302	11/1990	PCT			
BL	0 366 018	5/1990	Europe		*X	
BM	WO 88/10123	12/1988	PCT		*X	
BN	0 198 213 A2	10/1986	Europe			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

BO	H. Bail et al., "Histomorphometrical Evidence for the Bone Anabolic Effect of Species Specific Growth Hormone in Distraction Osteogenesis (DO)," <i>Intl. Soc. Fracture Repair</i> , 3/1998.
	H. Bail et al., "Rekombinantes Wachstumshormon beschleunigt die Kallusreifung bei der Distraktionsosteogenese", 1998. (English translation of Abstract only)
BP	R. Herrmann et al., "Comparison of the Thrombogenicity of Steel and Gold-Surface Coronary Stents with a Biodegradable, Drug Releasing Coating in a Human Stasis Model," <i>Circulation</i> 96 :4048, 1997.
BQ	R. Herrmann et al., "Comparison of the Thrombogenicity of Steel and Gold-Surface Coronary Stents with a Biodegradable, Drug Releasing Coating in a Human Stasis Model," <i>European Heart Journal</i> 18(152) :988, 1997.
BR	G. Schmidmaier et al., "Non-Linear Time Release Characteristics of a Biodegradable Polyactic Acid Stent Coating Releasing PEG-Hirudin and a PG12 Analog," <i>European Heart Journal</i> 18(571) :3316, 1997.
BS	G. Schmidmaier et al., "Neue Polylactid-Beschichtung für Koronarstents, die PEG-Hirudin und ein Prostacyclinanalog freisetzt, um die Aktivierung von Thrombozyten und der plasmatischen Gerinnung zu hemmen," <i>Z Kardiol</i> : 86(51) :304, 1997. (In German, no translation available)
BT	G. Schmidmaier et al., "Time Release Characteristics of a Biodegradable Stent Coating with Polylactic Acid Releasing PEG-Hirudin and PG12-Analog," <i>J Am Coll Cardiol</i> 29(94A) :927-3, 1997.
BU	G. Schmidmaier et al., "A New Biodegradable Polylactic Acid Coronary Stent-Coating, Releasing PEG-Hirudin and a Prostacycline Analog, Reduces Both Platelet Activation and Plasmatic Coagulation," <i>J Am Coll Cardiol</i> 29(354A) :771-5, 1997.
BV	H. Bail et al., "Species Specific Growth Hormone Accelerates Bone Regenerate Healing in Distraction Osteogenesis," <i>Proceedings from 2nd Consensus Meeting, European Tissue Repair Society</i> , 1997.
BW	H. Bail et al., "Recombinant Growth Hormone Increases Hard Callus Formation in Distraction Osteogenesis," 1997.
BX	L. Beck et al., "TGF- β , Induces Bone Closure of Skull Defects: Temporal Dynamics of Bone Formation in Defects Exposed to rhTGF- β ," <i>Journal of Bone and Mineral Research</i> 8(6) :753:761, 1993.
BY	S. Thaller et al., "The Effect of Insulin Growth Factor-1 on Calvarial Sutures in a Sprague-Dawley Rat," <i>The Journal of Craniofacial Surgery</i> 4(1) :35-39, January, 1993.

	BZ	J. Pfeilschifter et al., "Stimulation of Bone Matrix Apposition in Vitro by Local Growth Factors: A Comparison Between Insulin-like Growth Factor I, Platelet-Derived Growth Factor, and Transforming Growth Factor β ," <i>Endocrinology</i> 127 (1):69-75, 1990.
--	----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

